Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MARCKS siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MARCKS siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS). MARCKS is a membrane-associated protein involved in cell motility, actin cytoskeletal remodeling, and inflammatory signaling pathways. In preclinical research, MARCKS siRNA has been investigated for its potential therapeutic applications in various conditions, including inflammatory breast cancer (IBC), lung cancer, melanoma, and intimal hyperplasia, where it has been shown to inhibit cell migration, proliferation, and pro-tumor inflammatory activity.
- Other names
- anti-MARCKS siRNAMARCKS small interfering RNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)CaM (Calmodulin)F-actin (Filamentous actin)PIP2 (Phosphatidylinositol 4,5-bisphosphate)PKC (Protein kinase C family)STAT3 (Signal Transducer and Activator of Transcription 3)CDKN1B (Transmembrane emp24 domain-containing protein 7)MARCKS (Myristoylated alanine-rich protein kinase C substrate)
Beyond the preview
Go deeper on MARCKS siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MARCKS siRNA.